Biomarker Development

CHDR has a wide-ranging self-funded research programs where biomarkers are explored for pharmacological responses or other indicators related to a therapeutic intervention.

Technologies are developed and validated primarily to obtain detailed mechanistic information for use at the earliest clinical stage. Hence, we are able to establish decision points earlier, and thereby improve drug development timelines.

Technologies

• CNS test battery: a computerised assessment system
• Stable isotope administration
• Genomics and metabolomics
• MRI & PET Spectroscopy
• Plethysmography
• Novel assays such as PiCT, thrombin generation time, evaluation of platelet aggregation, coagulation
• Cardiac conduction and rhythmicity, including thorough QT
• Non-invasive airway inflammometry

Challenge tests are necessary to show the modulatory activity of drugs that have no clear effects under normal conditions. CHDR develops and validates challenge tests for a range of pharmacological systems.

Challenges:

• Cannabinoid
• Serotonergic
• Cholinergic
• Endovascular reactivity
• Metabolic and endocrine responses
• Immunological responsivity including LPS, CRP, SEB challenges
• Allergen challenge models
• Bronchoprovocation